Johnson & Johnson's good news, bad news day in talc court by Eric Sagonowsky Wednesday, May 22, 2019 As J&J continues to defend against allegations its talc powders can cause cancer, it prevailed in a South Carolina trial and lost in New York on Tuesday.
Investors aim to spotlight ties between pricing, exec pay by Eric Sagonowsky Tuesday, April 23, 2019 With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.
J&J's Gorsky says military service shaped his leadership style by Kyle Blankenship Friday, April 19, 2019 What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.
J&J chief Gorsky took a $9M pay hit but still nabbed $20M by Carly Helfand Friday, March 15, 2019 Johnson & Johnson hit—and exceeded—all its financial goals in 2018. So why did its top executive take a $9 million-plus pay cut?
'Troubled' about talc, senator wants asbestos info from J&J CEO by Eric Sagonowsky Wednesday, January 30, 2019 J&J has been battling lawsuits and damaging headlines over its talc powder, and now a senator is getting involved.
CEO told pharma to self-police pricing—then J&J hiked them by Eric Sagonowsky Friday, January 11, 2019 J&J's CEO said this week the pharma industry needs to police itself on pricing. Days later, his company raised prices on two dozen drugs.
Talc lawyer says J&J's woes strengthen his hand for settlement by Eric Sagonowsky Wednesday, December 19, 2018 What's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says.
J&J stock tumbles after Reuters report on asbestos in talc by Eric Sagonowsky Friday, December 14, 2018 Investors sent J&J's shares down Friday after Reuters reported on court documents detailing the company's internal debates over asbestos in talc.
